|
Volumn 5, Issue 4, 2005, Pages 259-261
|
Clinical management of eosinophilic gastrointestinal disorders
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ALENDRONIC ACID;
AMINO TERMINAL TELOPEPTIDE;
BISPHOSPHONIC ACID DERIVATIVE;
BUDESONIDE;
CALCIUM;
CORTICOSTEROID;
CROMOGLYCATE DISODIUM;
INTERLEUKIN 5 ANTIBODY;
IRON;
KETOTIFEN;
LEUKOTRIENE RECEPTOR BLOCKING AGENT;
OMALIZUMAB;
PLACEBO;
PROTON PUMP INHIBITOR;
RISEDRONIC ACID;
VITAMIN D;
ZOLEDRONIC ACID;
BONE DENSITY;
BONE TURNOVER;
CLINICAL PROTOCOL;
CLINICAL TRIAL;
DISEASE ASSOCIATION;
DRUG DOSE REGIMEN;
DRUG EFFICACY;
DRUG RESPONSE;
DUAL ENERGY X RAY ABSORPTIOMETRY;
EOSINOPHILIC GASTROENTERITIS;
ESOPHAGITIS;
ESOPHAGUS ULCER;
FOOD ALLERGY;
GASTROESOPHAGEAL REFLUX;
GASTROINTESTINAL SYMPTOM;
HUMAN;
IRON DEFICIENCY;
IRON DEFICIENCY ANEMIA;
NOTE;
OSTEOPENIA;
OSTEOPOROSIS;
PRICK TEST;
RISK BENEFIT ANALYSIS;
|
EID: 23844460156
PISSN: 15297322
EISSN: None
Source Type: Journal
DOI: 10.1007/s11882-005-0062-4 Document Type: Note |
Times cited : (18)
|
References (9)
|